Primary central nervous system lymphoma

This early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…

This phase 2 trial tests a combination of six drugs (TEDDI-R) in 48 adults with aggressive B-cell lymphoma that has spread to the central nervous system. The goal is to see if this mix can control the cancer better than current treatments. Participants receive the drugs in 21-day…

This early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…

This trial tests a type of engineered immune cell therapy called 19(T2)28z1xx CAR T cells in adults with B-cell cancers that have returned or not responded to treatment. The main goal is to find the highest dose that causes few or mild side effects. Researchers will also check wh…

This trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…

This early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering th…

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…

This phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery …

This early-phase trial tests a drug called glofitamab, given after a pre-treatment with obinutuzumab, in 20 adults with central nervous system lymphoma. The goal is to check safety and side effects. Glofitamab is a bispecific antibody that helps the immune system attack cancer ce…

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This phase 1/2 trial tests the drug acalabrutinib (Calquence) in 49 people with central nervous system lymphoma that has come back or not responded to treatment. Participants take the tablet by mouth twice daily. The study aims to find the safest dose and see if the drug can shri…

This study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and w…

This early-phase study tests a new treatment for patients with relapsed or hard-to-treat lymphoma in the brain or spinal cord. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and see if the treatme…

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This early-phase trial tests whether adding glucarpidase (Voraxaze) to standard methotrexate and rituximab can safely lower methotrexate levels in the blood for people with central nervous system lymphoma. About 58 participants will receive different doses of methotrexate along w…

This phase 2 trial tests tirabrutinib, a targeted cancer pill, in 119 people with primary central nervous system lymphoma (PCNSL), a rare brain cancer. Part A looks at patients whose cancer has returned or not responded to prior treatment. Part B tests tirabrutinib combined with …

This Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one c…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study reviews medical records of 36 adults with relapsed or refractory primary central nervous system lymphoma (PCNSL) who were treated with ibrutinib alone or with R-CHOP chemo. The goal is to see how many patients respond to treatment. PCNSL is a rare and aggressive brain …

This early-phase trial tests a new drug called GNC-038 in 7 people with relapsed or refractory central nervous system lymphoma (lymphoma that has spread to the brain or spine). The drug is a tetra-specific antibody designed to target cancer cells. The main goals are to check safe…

This study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning pat…

This study looks at whether a liquid biopsy (a simple test that checks for cancer DNA in spinal fluid) can better detect and monitor brain involvement in people with high-risk B-cell non-Hodgkin lymphoma. Researchers will compare this new method to standard tests in 64 newly diag…

This study follows 800 adults who have had their first ischemic stroke in Central Norway for up to 10 years. Researchers will track how physical activity, medication use, and control of blood pressure and cholesterol affect the risk of death, another stroke, or severe disability.…